Keros Therapeutics (NASDAQ:KROS) Given Buy Rating at Truist Financial

Truist Financial reissued their buy rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research report released on Tuesday, Benzinga reports. The firm currently has a $100.00 price objective on the stock.

Several other equities research analysts have also weighed in on KROS. HC Wainwright reiterated a buy rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday. William Blair reiterated an outperform rating on shares of Keros Therapeutics in a report on Wednesday, February 21st. Wedbush reissued an outperform rating and set a $86.00 price objective on shares of Keros Therapeutics in a research report on Thursday, February 29th. Finally, Piper Sandler reissued an overweight rating and set a $105.00 price objective on shares of Keros Therapeutics in a research report on Wednesday, March 27th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, Keros Therapeutics has an average rating of Buy and a consensus target price of $86.00.

Keros Therapeutics Stock Performance

KROS opened at $44.65 on Tuesday. The firm’s fifty day moving average is $53.34 and its two-hundred day moving average is $53.85. The firm has a market cap of $1.61 billion, a PE ratio of -8.67 and a beta of 1.25. Keros Therapeutics has a twelve month low of $27.02 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.12. The firm had revenue of $0.08 million during the quarter. The business’s revenue for the quarter was down 97.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.26) EPS. Equities analysts forecast that Keros Therapeutics will post -4.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Parkman Healthcare Partners LLC grew its position in Keros Therapeutics by 20.8% in the fourth quarter. Parkman Healthcare Partners LLC now owns 360,467 shares of the company’s stock valued at $14,332,000 after purchasing an additional 61,992 shares in the last quarter. Platinum Investment Management Ltd. bought a new position in Keros Therapeutics in the fourth quarter valued at $1,944,000. ADAR1 Capital Management LLC bought a new position in Keros Therapeutics in the fourth quarter valued at $27,367,000. China Universal Asset Management Co. Ltd. grew its position in Keros Therapeutics by 356.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock valued at $138,000 after purchasing an additional 2,702 shares in the last quarter. Finally, Braidwell LP grew its position in Keros Therapeutics by 18.7% in the third quarter. Braidwell LP now owns 1,357,309 shares of the company’s stock valued at $43,271,000 after purchasing an additional 213,444 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.